Nearly 50 residents and young consultants in Endocrinology and Nutrition met in Madrid for the first Emerging Experts programme, which focused on chronic hypoparathyroidism. Around 13,000 people in Spain are estimated to live with the disease, information from figures also reported by Las Provincias. The estimate is not linked to a national registry or an official epidemiological publication.
The programme brought younger doctors together with more experienced colleagues to discuss clinical cases and specialist training. Ascendis Pharma clinical information describes hypoparathyroidism as linked to a deficiency of parathyroid hormone, which helps regulate calcium and phosphate through its effects on the bones, kidneys and intestine.
Ascendis Pharma Iberia organised the meeting. Europa Press described it as the company's first educational project for young endocrinologists focused on chronic hypoparathyroidism. The format brought together scientific discussion, clinical case analysis and professional exchange between doctors at different stages of their careers.
The programme's clearest feature was its intergenerational format: senior specialists worked alongside younger endocrinologists and residents. Rather than relying on lectures alone, the sessions gave participants room to compare clinical experience through case-based discussion.
For younger doctors, the value of the meeting came from direct contact with colleagues with longer careers in endocrinology. Experienced specialists, in turn, helped develop doctors who may later manage rare and complex diseases. The report names no individual speakers and does not describe the cases discussed.
The condition requires more than keeping a calcium result within range. Hypoparathyroidism can be linked to neuromuscular excitability, kidney complications, extraskeletal calcifications and cognitive difficulties. Doctors may need to track several organ systems over time. Hormone-based treatment options have added to the need for careful long-term monitoring.
Alongside traditional calcium treatment and active forms of vitamin D, YORVIPATH is approved in the United States, the European Union, the European Economic Area and several other jurisdictions for adults with hypoparathyroidism. Treatment may require checks on calcium, phosphate, kidney function and possible complications.
Information from the organiser, Emerging Experts is intended to continue and support new generations of endocrinologists. Independent reporting has not cited an official assessment of learning outcomes or evidence of changes to clinical practice.
The programme's public-health relevance rests on the number of people affected and the disease's reach across several organs. The estimated 13,000 patients in Spain make specialist preparation a practical concern, even though chronic hypoparathyroidism is less common than other endocrine disorders.
Ascendis has also reported a long-term analysis from the PaTH Forward and PaTHway studies. It examines palopegteriparatide in relation to bone mineral density and a measure of bone structure; the results are due to be presented at ASBMR 2026. This information comes from the company and has not yet been assessed in an independent publication.
Those findings are separate from the Madrid meeting. The initiative announces neither a new treatment nor a change in medical policy. Its stated purpose is to build an ongoing training channel around chronic hypoparathyroidism through direct exchange between senior and young clinicians.
